Publication at Third Faculty of Medicine |
2019
Abstract
Worldwide, lung cancer is one of the most common oncological disease. Targeted analysis of the mutation status in non-small cell lung carcinoma detects 10-15 % of patients with a mutated epidermal growth factor receptor gene, whose presence is significant prognostically and therapeutically.
Diagnosis is based on molecular-genetic methods. Depending on the patient's performance status and type of mutation, the patient is indicated for therapy with tyrosine kinase inhibitors, which in this group of patients promise a good response to treatment with a favorable safety profile.